Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-1.84%
+1.11%
-0.22%
+0.32%
+28.68%
ABBV
AbbVie
$189.88
Chart
$183.34 (+3.57%)
$179.84 (+5.58%)
$203.01 (-6.47%)
$172.32 (+10.19%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-1.84%
+1.11%
-0.22%
+0.32%
+28.68%
ABBV
AbbVie
Current Price
$189.88
Strong Buy
Login to view AbbVie (ABBV) recommendation from the last 90 days from financial news and social media.
Chart
$183.34 (+3.57%)
$179.84 (+5.58%)
$203.01 (-6.47%)
$172.32 (+10.19%)
ABBV Latest Analysis
AbbVie to Acquire Capstan Therapeutics for $2.1B Boosting Autoimmune Pipeline.
Today
3 No-Brainer Stocks to Buy in July. Key PointsAbbVie offers something for every investor.
Mon Jul 7, 2025
How AbbVie is Engineering Its Next Growth Phase. AbbVie (NASDAQ:ABBV) has emerged as one of the standout performers in the healthcare sector this year with its stock climbing 6% while the broader S&.P 500 healthcare index declined 1%. This outperformance reflects investor confidence in the pharmaceutical giant’.s ambit
Mon Jul 7, 2025
FDA Accepts For Review Allergan Aesthetics Premarket Approval Application For Skinvive By Juvéderm . (RTTNews) - Allergan Aesthetics an AbbVie company (ABBV) Monday announced that the United States Food and Drug Administration (FDA) accepted for review the supplemental premarket approval (sPMA) application for Skinvive by Juvé.derm to reduce neck lines for the improvement of neck appear
Mon Jun 30, 2025
AbbVie to buy Capstan for up to $2.1 billion in immunology push.
Mon Jun 30, 2025
AbbVie to acquire Capstan Therapeutics for up to $2.1B in cash.
Mon Jun 30, 2025
AbbVie to Acquire Capstan Therapeutics Further Strengthening Commitment to Transforming Patient Care in Immunology. Capstan'.s lead asset CPTX2309 is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo and is a potential first-in-class product for treating B cell-mediated autoimmune diseasesProposed acquisition strengthens AbbVie'.s commitment to transforming the future of patient care
Mon Jun 30, 2025
AbbVie To Acquire Capstan Therapeutics In Up To $2.1 Bln All-Cash Deal . (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) and privately-held clinical-stage biotechnology company Capstan Therapeutics Inc. announced Monday a definitive agreement under which AbbVie will acquire Capstan including CPTX2309 a potential first-in-class in vivo tL
Mon Jun 30, 2025
AbbVie to buy Capstan Therapeutics for up to $2.1 billion.
Mon Jun 30, 2025
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock. ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira with more upside from a strong pipeline.
Fri Jun 27, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ABBV Stock trends
ABBV Stock performance
ABBV Stock analysis
ABBV investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings